Bridging the evidence-to-practice gap: Evaluating practice facilitation as a strategy to accelerate translation of a systems-level adherence intervention into safety net practices

资助家长奖纪要 项目证据(对CoVID检测和疫苗的认知)通过社会、伦理和 服务不足和/或弱势群体新冠肺炎检测的行为含义研究 人口倡议。项目证据利用NIMHD资助的家庭项目的基础设施 纽约大学朗格尼健康中心(FHC)，一个由联邦合格健康中心(FQHC)组成的网络 纽约市为超过125,000名低收入和种族和民族多元化的患者提供服务。项目证据是 一项三阶段社区参与研究，使用多管齐下的顺序混合方法设计，以获得 全面了解推动COVID检测和疫苗接种的多层次因素- 19名黑人和拉丁裔患者(主要结果)，以及参加安全网提供的后续护理 卫生系统。第一阶段是利用FHC电子健康记录(EHR)数据库进行定量检查 与接受聚合酶链式反应相关的个体水平的社会人口学、临床和医疗保健利用因素 在FHC接受护理的400名黑人和拉丁裔患者中进行新冠肺炎检测。这一阶段还将 使用经过验证的自我报告方法捕获测试的社区级和结构级决定因素 (NIH PhenX工具包)在相同患者中使用(目标1)。在阶段2中，来自阶段1的数据源是 结合定性数据(例如，焦点小组、人种学观察、文件分析)以获取 组织和道德问题，以阐明相关的重要社会、文化和背景因素 采用新冠肺炎测试和潜在疫苗(目标2)。与我们的社区监督合作 工作组(COTF)，在第三阶段，我们将整合第一阶段和第二阶段的数据，以提炼、测试和传播定制的数据 工具包和道德治理准则(例如，临床试验透明度和数据隐私)(目标3)。这些 工具包的设计将增加对新冠肺炎检测和疫苗研究的知识和认识 将在FHC、当地社区、NYULH和RADx UP协调和 数据收集中心。

Summary of the Funded Parent Award Project EVIDENCE (pErception of coVID tEsting aNd vaccine) was funded through the Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations initiative. Project EVIDENCE leverages the infrastructure of a NIMHD-funded project in the Family Health Centers (FHCs) of NYU Langone Health, a network of federally qualified health centers (FQHC) in NYC that serves over 125,000 low-income and racially and ethnically diverse patients. Project EVIDENCE is a three-phase community-engaged study that uses a multipronged, sequential mixed methods design to gain a comprehensive understanding of the multilevel factors that drive uptake of testing and vaccination for COVID- 19 of Black and Latinx patients (primary outcome), and participation in follow-up care offered by safety-net health systems. Phase 1 is utilizing the FHC electronic health record (EHR) database to quantitatively examine individual-level sociodemographic, clinical, and healthcare utilization factors associated with receiving a PCR test for COVID-19 among 400 Black and Latinx patients who receive care at the FHCs. This phase will also capture the community- and structural-level determinants of testing using validated self-report measures (NIH PhenX Toolkit) among the same patients (Aim 1). In Phase 2 the data sources from Phase 1 are being coupled with qualitative data (e.g., focus groups, ethnographic observation, document analysis) to capture organizational and ethical issues to shed light on important social, cultural, and contextual factors associated with uptake of COVID-19 testing and potential vaccine (Aim 2). In partnership with our Community Oversight Task Force (COTF), in Phase 3, we will integrate Phase 1 and 2 data to refine, test, and disseminate tailored toolkits and ethical governance guidelines (e.g. clinical trials transparency and data privacy) (Aim 3). These toolkits will be designed to increase knowledge and awareness of COVID-19 testing and vaccine research and will be widely disseminated among the FHCs, local community, NYULH, and the RADx UP Coordination and Data Collection Center.